The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology

Jithma Prasad Abeykoon, Luke Mueller, Frank Dong, Ashish Chintakuntlawar, Jonas Paludo, Rami Mortada

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Thyroid nodules are classified into six cytological categories under the Bethesda classification system. Two of these categories, atypical of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), are further labeled as “indeterminate” diagnosis. Starting in June, 2012, Kansas University-Wichita Endocrine clinic implemented Afirma® Gene Expression Classifier (AGEC) to evaluate the need for surgical resection of thyroid nodules in patients with an indeterminate diagnosis. Electronic medical records of patients who underwent thyroid nodule fine-needle aspiration from 2004–2014 were reviewed. The aim of this study was to find whether implementing AGEC was associated with decreased surgical recommendation rate, decreased cost, and increased incidence of thyroid malignancy diagnosed by surgery in patients with indeterminate diagnosis. A total of 299 consecutive patients’ charts were screened. Sixty-one (20 %) patients had an indeterminate diagnosis. Out of these, 27 (44 %) patients underwent evaluation before and 34 (56 %) patients underwent evaluation after AGEC implementation, respectively. Surgical recommendation for patients with indeterminate finding decreased from 81.5 to 50 % (p = 0.01) after AGEC implementation. Surgical pathology was read as malignant in 20 and 85.7 % (p < 0.01) of patients before and after AGEC implementation, respectively. Primary cost-benefit estimate showed implementing AGEC has saved $1048/patient in medical evaluation and initial management of patients with indeterminate diagnosis. AGEC implementation has decreased the number of surgical recommendations, has lowered financial burden, and has increased incidence of thyroid malignancy diagnosed by surgical pathology in patients with indeterminate diagnosis of thyroid nodules.

Original languageEnglish (US)
Pages (from-to)272-278
Number of pages7
JournalHormones and Cancer
Volume7
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Thyroid Nodule
Cell Biology
Gene Expression
Surgical Pathology
Thyroid Gland
Neoplasms
Electronic Health Records
Incidence
Fine Needle Biopsy
Cost-Benefit Analysis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Endocrine and Autonomic Systems
  • Cancer Research

Cite this

The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology. / Abeykoon, Jithma Prasad; Mueller, Luke; Dong, Frank; Chintakuntlawar, Ashish; Paludo, Jonas; Mortada, Rami.

In: Hormones and Cancer, Vol. 7, No. 4, 01.08.2016, p. 272-278.

Research output: Contribution to journalArticle

Abeykoon, Jithma Prasad ; Mueller, Luke ; Dong, Frank ; Chintakuntlawar, Ashish ; Paludo, Jonas ; Mortada, Rami. / The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology. In: Hormones and Cancer. 2016 ; Vol. 7, No. 4. pp. 272-278.
@article{003a5fc9d7194301b8cc831a8dd72d1e,
title = "The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology",
abstract = "Thyroid nodules are classified into six cytological categories under the Bethesda classification system. Two of these categories, atypical of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), are further labeled as “indeterminate” diagnosis. Starting in June, 2012, Kansas University-Wichita Endocrine clinic implemented Afirma{\circledR} Gene Expression Classifier (AGEC) to evaluate the need for surgical resection of thyroid nodules in patients with an indeterminate diagnosis. Electronic medical records of patients who underwent thyroid nodule fine-needle aspiration from 2004–2014 were reviewed. The aim of this study was to find whether implementing AGEC was associated with decreased surgical recommendation rate, decreased cost, and increased incidence of thyroid malignancy diagnosed by surgery in patients with indeterminate diagnosis. A total of 299 consecutive patients’ charts were screened. Sixty-one (20 {\%}) patients had an indeterminate diagnosis. Out of these, 27 (44 {\%}) patients underwent evaluation before and 34 (56 {\%}) patients underwent evaluation after AGEC implementation, respectively. Surgical recommendation for patients with indeterminate finding decreased from 81.5 to 50 {\%} (p = 0.01) after AGEC implementation. Surgical pathology was read as malignant in 20 and 85.7 {\%} (p < 0.01) of patients before and after AGEC implementation, respectively. Primary cost-benefit estimate showed implementing AGEC has saved $1048/patient in medical evaluation and initial management of patients with indeterminate diagnosis. AGEC implementation has decreased the number of surgical recommendations, has lowered financial burden, and has increased incidence of thyroid malignancy diagnosed by surgical pathology in patients with indeterminate diagnosis of thyroid nodules.",
author = "Abeykoon, {Jithma Prasad} and Luke Mueller and Frank Dong and Ashish Chintakuntlawar and Jonas Paludo and Rami Mortada",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s12672-016-0263-4",
language = "English (US)",
volume = "7",
pages = "272--278",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "4",

}

TY - JOUR

T1 - The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology

AU - Abeykoon, Jithma Prasad

AU - Mueller, Luke

AU - Dong, Frank

AU - Chintakuntlawar, Ashish

AU - Paludo, Jonas

AU - Mortada, Rami

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Thyroid nodules are classified into six cytological categories under the Bethesda classification system. Two of these categories, atypical of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), are further labeled as “indeterminate” diagnosis. Starting in June, 2012, Kansas University-Wichita Endocrine clinic implemented Afirma® Gene Expression Classifier (AGEC) to evaluate the need for surgical resection of thyroid nodules in patients with an indeterminate diagnosis. Electronic medical records of patients who underwent thyroid nodule fine-needle aspiration from 2004–2014 were reviewed. The aim of this study was to find whether implementing AGEC was associated with decreased surgical recommendation rate, decreased cost, and increased incidence of thyroid malignancy diagnosed by surgery in patients with indeterminate diagnosis. A total of 299 consecutive patients’ charts were screened. Sixty-one (20 %) patients had an indeterminate diagnosis. Out of these, 27 (44 %) patients underwent evaluation before and 34 (56 %) patients underwent evaluation after AGEC implementation, respectively. Surgical recommendation for patients with indeterminate finding decreased from 81.5 to 50 % (p = 0.01) after AGEC implementation. Surgical pathology was read as malignant in 20 and 85.7 % (p < 0.01) of patients before and after AGEC implementation, respectively. Primary cost-benefit estimate showed implementing AGEC has saved $1048/patient in medical evaluation and initial management of patients with indeterminate diagnosis. AGEC implementation has decreased the number of surgical recommendations, has lowered financial burden, and has increased incidence of thyroid malignancy diagnosed by surgical pathology in patients with indeterminate diagnosis of thyroid nodules.

AB - Thyroid nodules are classified into six cytological categories under the Bethesda classification system. Two of these categories, atypical of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), are further labeled as “indeterminate” diagnosis. Starting in June, 2012, Kansas University-Wichita Endocrine clinic implemented Afirma® Gene Expression Classifier (AGEC) to evaluate the need for surgical resection of thyroid nodules in patients with an indeterminate diagnosis. Electronic medical records of patients who underwent thyroid nodule fine-needle aspiration from 2004–2014 were reviewed. The aim of this study was to find whether implementing AGEC was associated with decreased surgical recommendation rate, decreased cost, and increased incidence of thyroid malignancy diagnosed by surgery in patients with indeterminate diagnosis. A total of 299 consecutive patients’ charts were screened. Sixty-one (20 %) patients had an indeterminate diagnosis. Out of these, 27 (44 %) patients underwent evaluation before and 34 (56 %) patients underwent evaluation after AGEC implementation, respectively. Surgical recommendation for patients with indeterminate finding decreased from 81.5 to 50 % (p = 0.01) after AGEC implementation. Surgical pathology was read as malignant in 20 and 85.7 % (p < 0.01) of patients before and after AGEC implementation, respectively. Primary cost-benefit estimate showed implementing AGEC has saved $1048/patient in medical evaluation and initial management of patients with indeterminate diagnosis. AGEC implementation has decreased the number of surgical recommendations, has lowered financial burden, and has increased incidence of thyroid malignancy diagnosed by surgical pathology in patients with indeterminate diagnosis of thyroid nodules.

UR - http://www.scopus.com/inward/record.url?scp=84964350701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964350701&partnerID=8YFLogxK

U2 - 10.1007/s12672-016-0263-4

DO - 10.1007/s12672-016-0263-4

M3 - Article

C2 - 27102883

AN - SCOPUS:84964350701

VL - 7

SP - 272

EP - 278

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 4

ER -